The past period highlighted a series of significant events that took place at
Bristol-Myers Squibb (BMY). Despite a recent pullback in share prices, experts suggest this may present a buying opportunity. Amid a volatile biotech market, BMY delivered strong Q2 results and raised its full-year sales guidance, reflecting promising prospects and healthy growth momentum. A key development was BMY securing an FDA breakthrough status for its lung cancer drug, which can potentially be a game changer, despite the stock hitting a 52-week low. Analyst opinions diverge, with some cautioning due to mixed technical and fundamental signals. Declines in BMY’s shares, according to some experts, have gone too far, and the recent weakness should be bought. In terms of partnerships, BMY teamed up with Bain Capital to create a new company developing immunology drugs. However, the company cut its full-year adjusted view due to generic erosion faced by their legacy drugs. Investors heavily search for BMY, showing interest in their potential long-term income. Controversially, while Morgan Stanley and Goldman Sachs maintained sell and hold ratings, Jim Cramer was more optimistic, associating BMY with a breakthrough drug.
Bristol-Myers Squibb BMY News Analytics from Thu, 06 Feb 2025 08:00:00 GMT to Sat, 23 Aug 2025 16:06:02 GMT -
Rating 2
- Innovation 2
- Information 9
- Rumor 1
